Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMELIO Study: Anagliptin/Metformin Safety in Moderate Renal Impairment
jRCTs031200366Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of anagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Started May 2021; status: completed.
02
Drugs
anagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031200366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200366.